Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia

p38MAPK inhibitors attenuate cytokine production by bone marrow stromal cells and reduce stroma-mediated proliferation of acute lymphoblastic leukemia cells

(2011) Shivashni S. Gaundar et al.   CELL CYCLE

CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia

(2010) P. Rhein et al.   BLOOD

The Novel Activated Microglia/Macrophage WAP Domain Protein, AMWAP, Acts as a Counter-Regulator of Proinflammatory Response

(2010) M. Karlstetter et al.   JOURNAL OF IMMUNOLOGY

Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia

(2010) F Fei et al.   LEUKEMIA

Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib

(2010) Disha Dumka et al.   LEUKEMIA & LYMPHOMA

The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug Resistance in Chronic Myeloid Leukemia

(2009) Lars Klemm et al.   CANCER CELL

Adipocytes Impair Leukemia Treatment in Mice

(2009) J. W. Behan et al.   CANCER RESEARCH

CD38/CD31, the CCL3 and CCL4 Chemokines, and CD49d/Vascular Cell Adhesion Molecule-1 Are Interchained by Sequential Events Sustaining Chronic Lymphocytic Leukemia Cell Survival

(2009) A. Zucchetto et al.   CANCER RESEARCH

Upregulation of Monocyte/Macrophage HGFIN (Gpnmb/Osteoactivin) Expression in End-Stage Renal Disease

(2009) M. V. Pahl et al.   Clinical Journal of the American Society of Nephrology

First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults

(2009) Oliver G Ottmann et al.   CURRENT OPINION IN ONCOLOGY

The Dectin-2 family of C-type lectins in immunity and homeostasis

(2009) Lisa M. Graham et al.   CYTOKINE

The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer

(2009) Hae-Young Yong et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Cellular and molecular pathways linking inflammation and cancer

(2009) Chiara Porta et al.   IMMUNOBIOLOGY

Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

(2009) Kirk R. Schultz et al.   JOURNAL OF CLINICAL ONCOLOGY

Pre–B cell receptor–mediated cell cycle arrest in Philadelphia chromosome–positive acute lymphoblastic leukemia requiresIKAROSfunction

(2009) Daniel Trageser et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Ig-Like Transcript 3 Regulates Expression of Proinflammatory Cytokines and Migration of Activated T Cells

(2009) C.-C. Chang et al.   JOURNAL OF IMMUNOLOGY

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

(2009) Monique L Den Boer et al.   LANCET ONCOLOGY

In vitro secretion of matrix metalloprotease 9 is a prognostic marker in childhood acute lymphoblastic leukemia

(2009) Pascale Schneider et al.   LEUKEMIA RESEARCH

CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer

(2009) Cameron R Stewart et al.   NATURE IMMUNOLOGY

Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential role of the macrophage in terminating polymorphonuclear leukocyte influx

(2008) R. A. Dean et al.   BLOOD

Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors

(2008) Dan Jones et al.   CANCER

The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies

(2008) Pawel Robak et al.   LEUKEMIA & LYMPHOMA

Secretion of MMP-2 and MMP-9 induced by VEGF autocrine loop correlates with clinical features in childhood acute lymphoblastic leukemia

(2008) Florent Poyer et al.   LEUKEMIA RESEARCH